ArticleCell division2025
hsa-let-7b-5p-associated BUB1/TMPO-AS1 ceRNA axis identified as a potential biomarker in lung adenocarcinoma.
Article in Cell division, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBUB1, a key mitotic checkpoint kinase, is often dysregulated in cancer, yet its regulatory mechanism remains unclear. This study investigates the BUB1-centered miRNA-lncRNA-mRNA (ceRNA) network, its role in cell cycle regulation and immune modulation.
methodsPrognostic significance and expression profiles were assessed using TCGA-based databases such as KM Plotter, UALCAN, OncoDB, ENCORI, GEPIA2, Lung Cancer Explorer, and TCGAnalyzeR. Transcription factors were identified via Enrichr, and a ceRNA network was constructed using miRNet. Binding affinity and folding energy between BUB1, miRNA, and lncRNA were predicted using miRWalk and RNA22v2. Molecular docking evaluated interactions with natural compounds, chemotherapeutics, and inhibitor. Immune subpopulations were visualized using the SPRING viewer and correlation analysis with the immune cells was conducted using the GSCA and TIMER2.0 databases.
resultsBUB1 overexpression correlated with poor LUAD prognosis, especially in smokers (HR = 1.76), with transcriptomic analysis showing a 2.46 log2-fold increase in BUB1 transcript levels in tumor. TF-E2F1 and lncRNA-TMPO-AS1 were positively correlated with BUB1 (R = 0.664 and R = 0.632, respectively), while miRNA hsa-let-7b-5p showed a negative correlation (R = - 0.366). TMPO-AS1 exhibited an inverse association with hsa-let-7b-5p, suggesting a molecular sponge formation, repressing its tumor-suppressive activity. Docking revealed strong binding affinity of hesperidin (- 9.4 kcal/mol) with BUB1. Additionally, BUB1 expression negatively correlated with CD4⁺ T cells, suggesting an immunosuppressive role.
conclusionThis study identifies the BUB1/E2F1/TMPO-AS1/hsa-let-7b-5p axis as a potential prognostic biomarker and therapeutic target in LUAD. Targeting hsa-let-7b-5p may modulate this network, offering opportunities for both diagnostic and prognostic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.